focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Have gone through program, doesn't look like Physiomics have any Abstracts or Poster Sessions.
They do have an exhibition booth at C2 ( 24 exhibits total).
https://www.ecco-org.eu/Events/ENA2018/Exhibition-and-Sponsorship/Floorplan#floorplanoverviewform
Expect RNS for following
Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for
Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research.
Physiomics will host a stand for the full duration of the event, bringing it into contact with representatives of key academic and commercial organisations involved in the research and development of new cancer diagnostics and therapeutics.
https://www.physiomics-plc.com/physiomics-to-host-stand-at-eortc-dublin/
Have been doing some research on latest recruit, I'm wondering what she will be bringing to Physiomics as her background has not included oncology bio simulation. Not sure if company is branching off into a new area, or her background will bring something new to their Oncology program? Only time will tell, as Dr Jim Millen mentioned in latest video, she started full time in September.
Her latest update on Researchgate is "Rate and age-dependent damage elasticity formulation for efficient hip fracture simulation"
https://www.researchgate.net/publication/327539732_Rate_and_age-dependent_damage_elasticity_formulation_for_efficient_hip_fracture_simulations
and
HETEROGENEOUS DESIGN OPTIMISATION OF TISSUE ENGINEERING SCAFFOLDS:IN-VITRO ASSESSMENT OF A DIGITAL DESIGN FRAMEWORK.
http://cmbbe2018.tecnico.ulisboa.pt/pen_cmbbe2018/pdf/WEB_ABSTRACTS/Abstracts_CMBBE2018_129.pdf
Would love this to climb lot higher than what it is, but there's been about 1.25 million buys since Tuesday and there's not been much of a rise.
Utah, depends on any RNS being issued, if we break over 100 day moving average and sustain this, minimum it should drop then be low 4's.
Not bad, one day out from my chart prediction on Sunday.
Riddled, reading my charts, sp should start to tick up this week, hopefully Monday or Tuesday.
Confirmation from Merck that PYC has been involved with any of the regimes being displayed at ESMO conference, would be a bonus.
Also, if the decision making using VT pre clinical, or VT Clinical was helpful and cost effective to them in time and money.
Merck oncology updates at conference, wonder if PYC involved with any. European Society for Medical Oncology (ESMO) conference in Munich, Germany, Merck KGaA, Darmstadt, Germany will be presenting 39 abstracts in eight therapeutic agents across 14 tumor types, a “company record”. Ahead of the presentation at the Presidential Symposium on Sunday, October 21. http://www.pharmexec.com/esmo-spotlight-james-campbell-merck Quote from James Campell:- I think any leading company in our industry has to lean in the direction of being even more externally focused, even more connected to the external innovation eco-system, and being even more inclined to think boldly about new approaches to how we can best develop our science and our pipeline. For all the talent we have in-house, there are always going to be brilliant ideas in the external world that we need to tap into and access. We can achieve the very best results by connecting our ideas and in-house talent with the external world to drive our business towards the future
up for next financial year.
https://www.marketscreener.com/PHYSIOMICS-PLC-32526450/financials/
AI has arrived - PharmaTimes Magazine October 2018 hlttps://www.google.co.uk/url?sa=t&source=web&rct=j&url=http://www.pharmatimes.com/magazine/2018/october_2018/ai_has_arrived&ved=2ahUKEwi6uJu55-jdAhXjD8AKHfgcCUY4ChAWMAh6BAgDEAE&usg=AOvVaw0qvFJIzv25hIPUFvRNS-ff
Article written by Dr Hitesh Mistry whilst at Manchester University QSP Versus the Rest: Let the Competition Commence! Hitesh B. Mistry CPT: Pharmacometrics & Systems Pharmacology First published: 07 June 2018. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/psp4.12314 QSP :- Quantitative systems pharmacology
200k buy yesterday. 375k buy today. As mentioned at end of RNS on Monday, "please watch this space".
presentation of the company at the Jefferies Global Healthcare Conference being held in New York on June 5-8. The presentation is scheduled for 8:30 a.m. ET on Thursday, June 7. Has had positive effect on it's share price, as shot up over 6%.
DYOR The Merck Group, branded and commonly known as Merck, is a German multinational pharmaceutical, chemical and life sciences company headquartered in Darmstadt, with around 50,000 employees in around 70 countries. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world. The American pharmaceutical company Merck & Co. was established as a subsidiary of Merck in 1891, but was nationalized by the United States in 1917, before being privatized again when George W. Merck purchased back the stock in 1919. It is known as MSD (Merck Sharp and Dohme) outside of North America. The original Merck of Darmstadt holds the rights to the name Merck in all countries except the U.S. and Canada, where it is known as EMD (Emanuel Merck, Darmstadt). In 2015 Merck adopted a new logo and said it will be "much more aggressive" about protecting the brand of "the real Merck." It has initiated litigation in several countries against its former subsidiary Merck & Co. (MSD) over infringing use of the Merck name. In 2016, the High Court of Justice in the United Kingdom ruled that MSD had breached an agreement with its former parent company and that only Merck of Darmstadt is entitled to use the Merck name in the United Kingdom; the judge also held that MSD's use of "Merck" as part of branding on its global websites were directed to the UK and infringed Merck's trade mark rights in the UK.In response, MSD has initiated counter-litigation in the United States.
Sorry Formul1187 You've got wrong Merck. Prembolizumab = Keytruda= Merck Sharpe and Dohme(USA)